Please use this identifier to cite or link to this item:
|Title:||Quality by design (QbD)-based crystallization process development for the polymorphic drug tolbutamide|
|Citation:||Thirunahari, S., Chow, P.S., Tan, R.B.H. (2011-07-06). Quality by design (QbD)-based crystallization process development for the polymorphic drug tolbutamide. Crystal Growth and Design 11 (7) : 3027-3038. ScholarBank@NUS Repository. https://doi.org/10.1021/cg2003029|
|Abstract:||The thermodynamically stable Form II of the antidiabetic drug tolbutamide exhibits a thin fiber needle shape which renders it intractable for isolation and downstream processing. This work implements two in situ process analytical technology (PAT) methods, namely, attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) with orthogonal partial least-squares- principal component analysis (OPLS-PCA) for monitoring solute concentration, and Raman spectroscopy with dynamic PCA based multivariate statistical process monitoring (MSPM) for detection of solid form purity, to derive the robust design space for cooling crystallization of the desired Form IL. © 2011 American Chemical Society.|
|Source Title:||Crystal Growth and Design|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 14, 2018
WEB OF SCIENCETM
checked on Jun 18, 2018
checked on Jul 6, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.